Literature DB >> 25429486

Anaphylaxis to pegylated liposomal Doxorubicin: a case report.

L R Sharma1, A Subedi1, B K Shah2.   

Abstract

Liposomal doxorubicin is used for the treatment of various cancers like epithelial ovarian cancers, multiple myeloma and sarcomas. We report the first case of anaphylaxis to pegylated liposomal doxorubicin.

Entities:  

Year:  2014        PMID： 25429486      PMCID： PMC4663929          DOI： 10.7727/wimj.2013.270

Source DB:  PubMed          Journal:  West Indian Med J        ISSN： 0043-3144            Impact factor:   0.171


  5 in total

1.  Adverse drug reactions: definitions, diagnosis, and management.

Authors:  I R Edwards; J K Aronson
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

2.  Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies.

Authors:  J Szebeni; L Baranyi; S Savay; J Milosevits; R Bunger; P Laverman; J M Metselaar; G Storm; A Chanan-Khan; L Liebes; F M Muggia; R Cohen; Y Barenholz; C R Alving
Journal:  J Liposome Res       Date:  2002 Feb-May       Impact factor: 3.648

3.  Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

Authors:  Gabriella Ferrandina; Manuela Ludovisi; Domenica Lorusso; Sandro Pignata; Enrico Breda; Antonella Savarese; Pietro Del Medico; Laura Scaltriti; Dionyssios Katsaros; Domenico Priolo; Giovanni Scambia
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

4.  Doxorubicin-induced hypersensitivity reactions.

Authors:  D A Solimando; J P Wilson
Journal:  Drug Intell Clin Pharm       Date:  1984-10

5.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.

Authors:  A Chanan-Khan; J Szebeni; S Savay; L Liebes; N M Rafique; C R Alving; F M Muggia
Journal:  Ann Oncol       Date:  2003-09       Impact factor: 32.976
  5 in total
  1 in total

Review 1.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.